In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

“It’s a matter of how, for whom, and at what price?” Read more from Jonathan. Peak U.S. sales of Humira, made by pharmaceutical giant AbbVie, were $18.6 billion in 2022. Then, in ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...

Humira net revenues decreased 48.7% on an operational basis to $1.682 billion, Skyrizi net revenues rose 57.9% to $3.778 billion, and Rinvoq revenues gained 47.1% to $1.834 billion. “We are ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of exclusivity (LOE) for its blockbuster drug Humira while simultaneously ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

as its newer immunology drugs delivered growth needed to offset declining sales of its blockbuster Humira. The stock is on track for its biggest one-day percentage increase since March 26 ...

In terms of how Stelara’s loss of exclusivity is likely to play out, “we’ve talked about the Humira erosion curve being probably the best thing to model,” Jennifer Taubert, J&J’s ...